ArticlePloS one2025
A FtsZ inhibitor-acinetobactin conjugate with enhanced cellular uptake in Acinetobacter baumannii acts synergistically in combination with PBP3-targeting antibiotics.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic Insights into the Antimicrobial Effect of Benzodioxane-Benzamides AgainstAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug resistance in the Gram-negative bacterial pathogen Acinetobacter baumannii is a global public health threat, highlighting a critical need for drug development. FtsZ is an essential cell division protein that is an appealing target for new antibacterial agents. Benzamide-based FtsZ inhibitors have been developed that exhibit potent activity against Gram-positive pathogens, but poor activity against A. baumannii and other clinically significant Gram-negative pathogens. In this connection, we have initiated a program to enhance activity of benzamide FtsZ inhibitors via conjugation to iron-coordinating siderophore moieties that promote cellular uptake through endogenous bacterial siderophore-iron uptake pathways. Here, we describe a second-generation FtsZ inhibitor-siderophore conjugate (RUP7), in which an oxazole-benzamide FtsZ inhibitor is conjugated to acinetobactin, a principal native siderophore of A. baumannii. In iron-limiting conditions that are typically present at common sites of A. baumannii infection, RUP7 exhibits significantly enhanced activity against a library of A. baumannii clinical isolates relative to the non-conjugated FtsZ inhibitor (RUP2) or a first-generation conjugate (RUP4) in which RUP2 has been conjugated to a chlorocatechol siderophore functionality. This enhanced activity is correlated with markedly improved cellular uptake, perhaps via the BauABCDEF acinetobactin-iron uptake system, the expression of which is highly upregulated in iron-limiting conditions. RUP7 exhibits significant bactericidal synergy against A. baumannii when combined with clinical antibiotics that target penicillin binding protein 3 (PBP3 or FtsI), including aztreonam, piperacillin:tazobactam, cefsulodin, and ceftazidime. In the aggregate, our results highlight the combination of design-optimized FtsZ inhibitor-siderophore conjugates and PBP3-targeting antibiotics as an appealing therapeutic strategy for the treatment of A. baumannii infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.